

Disclaimer

10,543,179 B2 — Craig Boulton, Horsham (GB); Pascale Burtin, Huningue (FR); Oliver David, Mulhouse (FR); Ana de Vera, Basel (CH); Thomas Dumortier, Basel (CH); Irene Hunt, Basel (CH); Robert Schmouder, Berkeley Heights, NJ (US); William C. Collins, Basel (CH). DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR. Patent dated January 28, 2020. Disclaimer filed January 24, 2020, by the assignee, Novartis Pharmaceuticals Corporation.

Hereby disclaims the term of this patent which would extend beyond December 25, 2027.

(Official Gazette, March 3, 2020)